FHTX
Foghorn Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.92
+1.03%Aug 6, 2026, 00:00 UTC
Foghorn Therapeutics Inc. reported its Q2 2026 financial results, with collaboration revenue of $16.1 million, a net loss of $7.2 million, and diluted EPS of -$0.10.
Source: